Loading
A phase 1/2 trial of REC-1245 in non-Hodgkin lymphoma, run by Recursion Pharmaceuticals Inc., now recruiting.
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer is a phase 1/2 interventional study registered as NCT06678659 by Recursion Pharmaceuticals Inc., with 170 participants planned, started 2024-11-21 and due to reach its primary completion in 2028-10-30. Interventions recorded: REC-1245.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Recursion Pharmaceuticals and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/